Three AI Analyst Stocks, LSBK, EBS, and MNSO, Projected to Rise Over 20%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 01 2025
0mins
Source: TipRanks
AI Analyst Stocks with Significant Upside
- Overview of Selected Stocks: Lake Shore Bancorp (LSBK), Emergent BioSolutions (EBS), and MINISO Group Holdings (MNSO) are highlighted as stocks with over 20% upside potential as of September 1, 2025, according to the TipRanks AI Analyst Top Stocks Screener Tool.
Lake Shore Bancorp (LSBK)
- Company Profile: LSBK operates as the savings and loan holding company for Lake Shore Savings Bank, offering various banking products including savings accounts and money market accounts.
- Analyst Rating and Price Target: The AI analyst has assigned a score of 85 and a Buy rating, with a price target of $17.50, indicating a potential upside of 30.21%.
- Financial Performance: The company shows solid financial health with a robust balance sheet and consistent revenue growth, although technical indicators are neutral and valuation is deemed reasonable but not compelling.
Emergent BioSolutions (EBS)
- Company Profile: EBS is a global life sciences company focused on public health needs, particularly in biodefense and infectious disease.
- Analyst Rating and Price Target: The AI analyst has given it a score of 83 and a Buy rating, with a price target of $10, suggesting a 20.48% upside.
- Financial Challenges: While the stock score reflects strong valuation and positive sentiment from earnings calls, ongoing financial performance challenges and legal issues are noted as concerns. Technical indicators show positive momentum but caution is advised due to overbought signals.
MINISO Group Holdings (MNSO)
- Company Profile: MINISO is a global retailer known for affordable consumer products, including home décor, electronics, and fashion accessories.
- Analyst Rating and Price Target: The AI analyst has assigned a score of 83 and a Buy rating, with a price target of $30, indicating a potential upside of 20.72%.
- Financial Performance: The stock score is driven by strong financial performance and positive earnings sentiment, although technical indicators suggest strong momentum and caution is warranted due to overbought conditions. Valuation is reasonable but not compelling, which may limit upside potential.
Conclusion
- Investment Tool: Investors looking for stocks with significant upside potential can utilize the TipRanks AI Analyst Top Stocks Screener Tool to discover more opportunities similar to those mentioned.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EBS is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.900
Low
15.00
Averages
15.00
High
15.00
Current: 11.900
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement
- Insider Trading Lawsuit: New York Attorney General Letitia James has sued former CEO Robert G. Kramer for allegedly using nonpublic information to trade Emergent stock in 2020, undermining public trust.
- Settlement Agreement: Emergent has agreed to pay $900,000 in penalties and strengthen executive stock trading controls and policies, demonstrating the company's commitment to compliance and ethical governance.
- Vaccine Production Issues: The lawsuit highlights contamination problems discovered by Emergent in September and October 2020, leading to an FDA order to halt AstraZeneca production in April 2021, which adversely affected the company's production capacity and market reputation.
- Trading Plan Controversy: Kramer’s trading plan, approved in November 2020, allowed him to sell shares in January and February 2021, netting over $10.1 million, illustrating the legal risks associated with executive trading under insider information.
Continue Reading
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty
- Insider Trading Allegations: New York Attorney General Letitia James has sued Emergent's former CEO Robert Kramer for insider trading, alleging he executed a trading plan while aware of manufacturing and contamination issues, leading to a 13% drop in the company's stock price.
- Contract Background: Emergent inked a $261 million contract with AstraZeneca in 2020 to produce COVID-19 vaccines, but large quantities were rendered unusable due to contamination, adversely affecting the company's reputation and financial health.
- Fines and Settlement: Emergent agreed to pay $900,000 in penalties as part of a settlement with the Attorney General, while committing to improve executive trading policies to prevent future violations, demonstrating the company's focus on compliance.
- Market Reaction: Despite facing legal challenges, Emergent's stock has gained 15% over the past 12 months, and investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', indicating market confidence in the company's future prospects.
Continue Reading